





RealRate

PHARMACEUTICAL 2020

Phathom Pharmaceuticals Inc. Rank 163 of 358



The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 59% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	255,601
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,748
Liabilities, Non-Current	2,698
Other Assets	1,114
Other Compr. Net Income	0
Other Expenses	78,897
Other Liabilities	22,777
Other Net Income	-148,916
Other Revenues	0
Property and Equipment	463
Research and Development	20,374
Selling, General and Administrative Expense	6,944

Output Variable	Value in 1000 USD
Assets	257,178
Liabilities	29,223
Expenses	106,215
Revenues	0
Stockholders Equity	227,955
Net Income	-255,131
Comprehensive Net Income	-255,131
Economic Capital Ratio	96%